• DOI:10.1056/NEJMoa1500858
• Corpus ID: 23390149

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

@article{Sabatine2015EfficacyAS,
  title={Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.},
  author={Marc S. Sabatine and Robert P. Giugliano and Stephen D. Wiviott and Frederick J. Raal and Dirk Jacobus Blom and Jennifer G. Robinson and Christie M. Ballantyne and Ransi M. Somaratne and Jason C. Legg and Scott M. Wasserman and Rob Scott and Michael J Koren and Evan A. Stein},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 16},
  pages={
          1500-9
        }
}

• M. Sabatine, R. Giugliano, +10 authors E. Stein
• Published 2015
• Medicine, Biology
• The New England journal of medicine

BACKGROUND
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain longer-term data.

METHODS
In two open-label, randomized trials, we enrolled 4465 patients who had completed 1 of 12 phase 2 or 3 studies ("parent trials") of evolocumab. Regardless of study-group assignments in the parent trials, eligible patients were randomly assigned in a 2:1 ratio to receive either evolocumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy or standard therapy alone. Patients were followed for a median of 11.1 months with assessment of lipid levels, safety, and (as a prespecified exploratory analysis) adjudicated cardiovascular events including death, myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic attack, and heart failure. Data from the two trials were combined.

RESULTS
As compared with standard therapy alone, evolocumab reduced the level of LDL cholesterol by 61%, from a median of 120 mg per deciliter to 48 mg per deciliter (P<0.001). Most adverse events occurred with similar frequency in the two groups, although neurocognitive events were reported more frequently in the evolocumab group. The risk of adverse events, including neurocognitive events, did not vary significantly according to the achieved level of LDL cholesterol. The rate of cardiovascular events at 1 year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (hazard ratio in the evolocumab group, 0.47; 95% confidence interval, 0.28 to 0.78; P=0.003).

CONCLUSIONS
During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis. (Funded by Amgen; OSLER-1 and OSLER-2 ClinicalTrials.gov numbers, NCT01439880 and NCT01854918.).